239 related articles for article (PubMed ID: 38618505)
41. Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.
Stagaard R; Ley CD; Almholt K; Olsen LH; Knudsen T; Flick MJ
Blood Adv; 2018 Nov; 2(22):3126-3136. PubMed ID: 30459211
[TBL] [Abstract][Full Text] [Related]
42. Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout mice.
Bloem E; Karpf DM; Nørby PL; Johansen PB; Loftager M; Rahbek-Nielsen H; Petersen HH; Blouse GE; Thim L; Kjalke M; Bolt G
J Thromb Haemost; 2019 Feb; 17(2):350-360. PubMed ID: 30525289
[TBL] [Abstract][Full Text] [Related]
43. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
Hubbard AR; Rigsby P; Barrowcliffe TW
Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
[TBL] [Abstract][Full Text] [Related]
44. Improved intravenous lentiviral gene therapy based on endothelial-specific promoter-driven factor VIII expression for hemophilia A.
Gong J; Yang R; Zhou M; Chang LJ
Mol Med; 2023 Jun; 29(1):74. PubMed ID: 37308845
[TBL] [Abstract][Full Text] [Related]
45. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.
Kroner PA; Friedman KD; Fahs SA; Scott JP; Montgomery RR
J Biol Chem; 1991 Oct; 266(29):19146-9. PubMed ID: 1918030
[TBL] [Abstract][Full Text] [Related]
46. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02/150).
Hubbard AR; Heath AB
J Thromb Haemost; 2004 Aug; 2(8):1380-4. PubMed ID: 15304044
[TBL] [Abstract][Full Text] [Related]
47. Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non-severe haemophilia A.
Rejtő J; Königsbrügge O; Grilz E; Hofer S; Mauracher LM; Gabler C; Schuster G; Feistritzer C; Sunder-Plaßmann R; Quehenberger P; Gebhart J; Ay C; Pabinger I
J Thromb Haemost; 2020 May; 18(5):1081-1086. PubMed ID: 32073230
[TBL] [Abstract][Full Text] [Related]
48. MicroRNA and Hemophilia-A Disease: Bioinformatics Prediction and Experimental Analysis.
Rezaei H; Motovali-Bashi M; Mowla SJ
Cell J; 2021 Aug; 23(3):341-348. PubMed ID: 34308578
[TBL] [Abstract][Full Text] [Related]
49. Phenotype-genotype correlations in hemophilia A carriers are consistent with the binary role of the phase between F8 and X-chromosome inactivation.
Radic CP; Rossetti LC; Abelleyro MM; Tetzlaff T; Candela M; Neme D; Sciuccati G; Bonduel M; Medina-Acosta E; Larripa IB; de Tezanos Pinto M; De Brasi CD
J Thromb Haemost; 2015 Apr; 13(4):530-9. PubMed ID: 25611311
[TBL] [Abstract][Full Text] [Related]
50. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
[TBL] [Abstract][Full Text] [Related]
51. Influence of single nucleotide polymorphisms in factor VIII and von Willebrand factor genes on plasma factor VIII activity: the ARIC Study.
Campos M; Buchanan A; Yu F; Barbalic M; Xiao Y; Chambless LE; Wu KK; Folsom AR; Boerwinkle E; Dong JF
Blood; 2012 Feb; 119(8):1929-34. PubMed ID: 22219226
[TBL] [Abstract][Full Text] [Related]
52. Differential proteolytic activation of factor VIII-von Willebrand factor complex by thrombin.
Hill-Eubanks DC; Parker CG; Lollar P
Proc Natl Acad Sci U S A; 1989 Sep; 86(17):6508-12. PubMed ID: 2505252
[TBL] [Abstract][Full Text] [Related]
53. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
54. Are Iranian patients with von Willebrand disease type 2N properly differentiated from hemophilia A and do they receive appropriate treatment?
Seidi Zadeh O; Ahmadinejad M; Amoohossein B; Homayoun S
Blood Coagul Fibrinolysis; 2020 Sep; 31(6):382-386. PubMed ID: 32815913
[TBL] [Abstract][Full Text] [Related]
55. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
Saenko EL; Shima M; Gilbert GE; Scandella D
J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
[TBL] [Abstract][Full Text] [Related]
56. Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.
Aly AM; Hoyer LW
J Clin Invest; 1992 May; 89(5):1382-7. PubMed ID: 1569181
[TBL] [Abstract][Full Text] [Related]
57. Next-generation sequencing of von Willebrand factor and coagulation factor VIII genes: a cross-sectional study in Croatian adult patients diagnosed with von Willebrand disease.
Lapić I; Radić Antolic M; Boban A; Coen Herak D; Rogić D; Zadro R
Croat Med J; 2022 Apr; 63(2):166-175. PubMed ID: 35505650
[TBL] [Abstract][Full Text] [Related]
58. Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors.
Biguzzi E; Castelli F; Lijfering WM; Cannegieter SC; Eikenboom J; Rosendaal FR; van Hylckama Vlieg A
Thromb Res; 2021 Jan; 197():172-178. PubMed ID: 33221577
[TBL] [Abstract][Full Text] [Related]
59. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
60. Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.
Goudemand J; Mazurier C; Marey A; Caron C; Coupez B; Mizon P; Goudemand M
Br J Haematol; 1992 Feb; 80(2):214-21. PubMed ID: 1550779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
